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Innovative PCR tests for rapid and accurate diagnosis of infections represent a
challenge for laboratory budgets. Some laboratory managers have been more suc-
cessful than others to obtain funding for novel technologies for which no tariffs
exist. OBJECTIVES: This project aimed to understand critical issues of the funding
and purchasing process as well as key factors for positive funding decisions to
introduce molecular technologies in Italy. METHODS: We conducted a 2-phase
health care use project. Phase 1 included a landscape analysis, stakeholder map-
ping and interviews with non-users and users of molecular assays. Phase 2 con-
sisted of a workshop with key players involved at various levels in the funding and
purchase decision process. RESULTS: Successful microbiologists have succeeded
in transferring the understanding of the innovative technique’s value for the hos-
pital to the Strategic Direction. Directors of Microbiology of Complex Units, and/or
with the process of reorganization of Laboratory Medicine Departments com-
pleted, have more decision power and are expected to introduce innovative diag-
nostics. The Federation of Regional Superintendents and Treasurers of Health
(FARE) plays an important role in the request/tender process. The non-inclusion of
a new diagnostic test in the Tariff Nomenclature is not a major obstacle in the
decision making process as new techniques can be adopted by “assimilation”. The
Italian health care system is characterized by its regionalization. Policies and pri-
orities of introduction, funding and purchasing of new diagnostic technologies for
Regional Health Plans and Health Funds differ greatly. CONCLUSIONS: The deci-
sion to introduce innovative technologies must be aligned with the objectives of
the respective Regional Health Plans. Through rapid and accurate diagnosis, PCR
tests improve patient management. The case needs to be made to the Strategic
Direction of hospitals, to the Superintendents managing the request process, and
reinforced with future prospective studies.
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OBJECTIVES: Promotion of generic drug utilization to reduce patient’s out-of-
pocket costs and improve insurance finance is a cross-national policy. The share of
generics in Japan, 8.6% on a value basis, is lower than in other OECD countries.
Although safety concerns, inventory management, drug charge margins and pa-
tient/physician brand preferences are cited as restraints to adoption of generic
drugs prescriptions, their price-setting remains to be studied empirically. The pur-
pose of this study is to verify the effects of price markups/levels of generic drugs on
their prescription in hospitals under Diagnosis-Procedure-Combination (DPC)
based payment system considered unaffected by drug charge margins and wherein
prescription of the lowest-priced generic drugs is economically rational.
METHODS: A retrospective cohort study of inpatients with drug prescriptions for
which generic drug is already marketed. 732 drugs of 20 categories from among
calcium channel blockers, gastric secretion inhibitors, antibacterial drugs, hEPOs,
cancer drugs and radiocontrast agents were included. Data were collected from 980
acute care hospitals in Japan during April 1, 2010 to March 31, 2011. RESULTS: A
total of 2,768,456 (54.9%) among the study population of 5,041,157 cases were ana-
lyzed. An average of six price ranges existed for each dosage form of each drug, and
price variability, such as 89 price ranges in total for calcium channel blockers, was
found. Even after adjusting for other covariates, the share of prescriptions of the
highest-priced generic drugs was the greatest among the price ranges of generic
drug. CONCLUSIONS: Physician prescription was nearly uninfluenced by markups.
Out results suggest that positive financial effects on medical insurance may result
from lowering prices of generic drug in the highest price range rather than by
aggregating those in the lowest range.
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OBJECTIVES:A former study indicated that clinical trial related activities generated
250-300 million USD revenue in 2008 for Hungarian health care providers and clin-
ical research organizations, and so 0.15% of the Hungarian GDP was attributable to
clinical trials. The purpose of this study was to measure the total annual value of
investigational medical products (IMPs) provided by sponsors in clinical trials in
Hungary. METHODS: All phase II-IV trials licensed in Hungary in 2010 were se-
lected to assess value of IMPs due to savings from free supply of drugs for patients
treated in clincal trials. Phase I and bioequivalence studies were excluded since
participants are healthy volunteers without need for treatment. We retrieved the
following data from clinical trial master files at the Directorate General of National
Institute of Pharmacy: EudraCT number, full title of the trial, therapeutic area,
interventions, length of treatment, product names, number of treatment arms in
the trial, planned number of study participants in Hungary, study design, clinical
trial authorisation date. Drug prices were estimated based on the price of compar-
ator or similar drugs in the same therapeutic area. 290 HUF/Euro exchange rate was
applied. RESULTS: The estimated annual value of IMPs in phase II-IV clinical trials
was 29 million € in Hungary in 2010. Phase III. trials contributed by 65% to the total
amount, while phase II and phase IV trials added 15% and 20%. The value of IMPs
depended on the therapeutic area. CONCLUSIONS: Significant savings could be
generated from avoided drug costs for clinical trial participants, the value of IMPs
was equal with 2,5% of the public pharmaceutical budget (1,18 billion €) by the
National Health Insurance Fund. Our study confirms a neglected economic benefit
of clinical trials.
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OBJECTIVES: In public funded health care systems accessibility (time to decision)
to new medicines is crucially dependent on the assessment process by the compe-
tent Authorities. In Portugal, since 2007, new medicines are explicitly (hospital) or
implicitly (ambulatory) assessed (cost and effectiveness) by the Portuguese Minis-
try of Health (PMH) before they can be purchased (financed) by hospitals or Re-
gional Health Authorities, respectively. This study aimed to measure time to fi-
nancing decision from the PMH using survival analysis and confront the results to
the maximum decision timelines established in the Law: 70 days (hospital) and 110
days (ambulatory). METHODS: A questionnaire was designed to collect data from
the pharmaceutical companies submitting reimbursement applications of new
medicines or medicines with new therapeutic indications (NMNTI) to the PMH
between January 2007 and June 2011. A total of 119 NMNTI were analyzed using the
Turnbull non-parametric estimator and Accelerated Failure Time regression mod-
els with Gaussian mixture distributions allowing for interval, left and right censor-
ing. Model selection was conducted by backward stepwise elimination based on
Akaike’s Information Criterion. RESULTS: Median time from application to PMH
decision was 292 days (95%CI: 270-336) in ambulatory and 481 days (95%CI: 398-819)
in hospital medicines. Evidence was found that these decision times were signifi-
cantly (p0.001) increased when the therapeutic value assessment was based on
expert panels (63%), multiple comparators (22%) and Oxford CEBM level of evidence
less than 1A (19%); and economic value assessment was relative to cardiovascular
(58%) or immunomodulatory non-oncology medicines (44%) and included an eco-
nomic evaluation study proactively provided by pharmaceutical companies (37%)
or enforced by the PMH (103%). CONCLUSIONS: Adequate survival analysis is use-
ful to understand accessibility to new medicines or medicines with new therapeu-
tic indications. Furthermore, substantial problems were found in the accessibility
to these medicines in Portugal since 2007.
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OBJECTIVES: Public funding of medicines is a key health policy instrument for
governments in virtually all countries in the world. Given the typical requirement
of a prior assessment, the decisions of health authorities, and the speed with which
they are taken, are critical determinants in the accessibility to medicines with new
molecules or therapeutic indications. This research has as a principle objective the
use of extreme value statistics in assessing the probability of long decision times
associated with public funding requests of medicines in Portugal. METHODS: The
time to final decision on public funding for 119 medicines with market authoriza-
tion between January of 2007 and June of 2011 was analyzed using an adaptation of
the semi-parametric Peaks-Over-Threshold maximum likelihood methodology for
censored survival data. The methodology assumes that for the majority of distri-
butions, conditional on certain theoretical arguments common to extreme value
statistics, excesses over a suitable large threshold can be modeled with a General-
ized Pareto distribution. RESULTS: A non-negligible probability of 6.6% was esti-
mated of the time until the final decision on public funding going beyond 3 years.
The estimated probability is reduced to 2.8% at 3.5 years and 0.7% at 4 years.
Despite the existence of various long processes, a finite endpoint was estimated to
the distribution of decision times, pointing at, under the current circumstances, no
process taking longer than 1672 days (4.6 years). CONCLUSIONS: Extreme value
statistics, allowing for a more accurate modeling of the tail of survival distributions
than would be possible with standard survival techniques, is a valuable tool in
assessing the probability of long decision times associated with public funding
requests of medicines.
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OBJECTIVES: In France assessments by the Transparency Committee (TC) plays a
significant role in pricing and market access of new products. TC evaluates clinical
efficacy and safety data of new interventions, and compares it to current standard
of care. TC’s assessments are made using ASMR ratings ranging from I to V (major
innovation to no improvement). The objective of this study was to understand
trends in TC’s assessments for new products approved by the EMA in 2011-2012.
METHODS: TC’s assessments for 11 products approved by the EMA during 2011-
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